Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Jun 1;89(11):5103–5107. doi: 10.1073/pnas.89.11.5103

Chimpanzees immunized with recombinant soluble CD4 develop anti-self CD4 antibody responses with anti-human immunodeficiency virus activity.

M Watanabe 1, J E Boyson 1, C I Lord 1, N L Letvin 1
PMCID: PMC49237  PMID: 1594618

Abstract

In view of the efficiency with which human immunodeficiency virus replication can be blocked in vitro with anti-CD4 antibodies, the elicitation of an anti-CD4 antibody response through active immunization might represent a useful therapeutic strategy for AIDS. Here we demonstrate that immunization of chimpanzees with recombinant soluble human CD4 elicited an anti-CD4 antibody response. The elicited antibody bound self CD4 on digitonin-treated but not freshly isolated lymphocytes. Nevertheless, this antibody blocked human immunodeficiency virus replication in chimpanzee and human lymphocytes. These observations suggest that immunization with recombinant soluble CD4 from human immunodeficiency virus-infected humans may be feasible and therapeutically beneficial.

Full text

PDF
5103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Blue M. L., O'Brien C., Schlossman S. F. Monoclonal antibodies reactive with the T cell receptor zeta chain: production and characterization using a new method. J Immunol. 1989 Sep 15;143(6):1899–1904. [PubMed] [Google Scholar]
  2. Camerini D., Seed B. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site. Cell. 1990 Mar 9;60(5):747–754. doi: 10.1016/0092-8674(90)90089-w. [DOI] [PubMed] [Google Scholar]
  3. Cassatt D. R., Sweet R. W., Arthos J. A., Truneh A. Immunization with soluble murine CD4 induces an anti-self antibody response without causing impairment of immune function. J Immunol. 1991 Sep 1;147(5):1470–1476. [PubMed] [Google Scholar]
  4. Celada F., Cambiaggi C., Maccari J., Burastero S., Gregory T., Patzer E., Porter J., McDanal C., Matthews T. Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J Exp Med. 1990 Oct 1;172(4):1143–1150. doi: 10.1084/jem.172.4.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fisher R. A., Bertonis J. M., Meier W., Johnson V. A., Costopoulos D. S., Liu T., Tizard R., Walker B. D., Hirsch M. S., Schooley R. T. HIV infection is blocked in vitro by recombinant soluble CD4. Nature. 1988 Jan 7;331(6151):76–78. doi: 10.1038/331076a0. [DOI] [PubMed] [Google Scholar]
  6. Hasunuma T., Tsubota H., Watanabe M., Chen Z. W., Lord C. I., Burkly L. C., Daley J. F., Letvin N. L. Regions of the CD4 molecule not involved in virus binding or syncytia formation are required for HIV-1 infection of lymphocytes. J Immunol. 1992 Mar 15;148(6):1841–1846. [PubMed] [Google Scholar]
  7. Healey D., Dianda L., Moore J. P., McDougal J. S., Moore M. J., Estess P., Buck D., Kwong P. D., Beverley P. C., Sattentau Q. J. Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. J Exp Med. 1990 Oct 1;172(4):1233–1242. doi: 10.1084/jem.172.4.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kahn J. O., Allan J. D., Hodges T. L., Kaplan L. D., Arri C. J., Fitch H. F., Izu A. E., Mordenti J., Sherwin J. E., Groopman J. E. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med. 1990 Feb 15;112(4):254–261. doi: 10.7326/0003-4819-112-4-. [DOI] [PubMed] [Google Scholar]
  9. Schooley R. T., Merigan T. C., Gaut P., Hirsch M. S., Holodniy M., Flynn T., Liu S., Byington R. E., Henochowicz S., Gubish E. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med. 1990 Feb 15;112(4):247–253. doi: 10.7326/0003-4819-112-4-247. [DOI] [PubMed] [Google Scholar]
  10. Watanabe M., Chen Z. W., Tsubota H., Lord C. I., Levine C. G., Letvin N. L. Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):120–124. doi: 10.1073/pnas.88.1.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Watanabe M., Levine C. G., Shen L., Fisher R. A., Letvin N. L. Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4616–4620. doi: 10.1073/pnas.88.11.4616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Watanabe M., Reimann K. A., DeLong P. A., Liu T., Fisher R. A., Letvin N. L. Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature. 1989 Jan 19;337(6204):267–270. doi: 10.1038/337267a0. [DOI] [PubMed] [Google Scholar]
  13. Watanabe M., Ringler D. J., Fultz P. N., MacKey J. J., Boyson J. E., Levine C. G., Letvin N. L. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol. 1991 Jun;65(6):3344–3348. doi: 10.1128/jvi.65.6.3344-3348.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES